Compare CubeSmart (CUBE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs TG Therapeutics Inc — how do they compare? CubeSmart trades at $40.86 (market cap $9.20B), while TG Therapeutics Inc trades at $50 (market cap $7.64B). The key difference: CubeSmart is the larger of the two by market cap, and CubeSmart pays a 5.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CUBE | TGTX | |
|---|---|---|
Market Cap | $9.20B | $7.64B |
Sector | Real Estate | Health |
52-Week High | $42.50 | $59.06 |
52-Week Low | $35.36 | $26.94 |
Enterprise Value | $12.72B | $7.84B |
Dividend Yield | 5.19% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
